58610-69-8 Usage
General Description
2-(pyrrolidin-1-ylmethyl)-1H-imidazole is a chemical compound with potential applications in pharmaceuticals and research. It is a heterocyclic compound containing both a pyrrolidinyl and an imidazole moiety. The pyrrolidinyl group is a five-membered ring structure that is commonly found in many natural products and pharmaceutical drugs, while the imidazole group is a five-membered ring containing two nitrogen atoms, making it an important functional group in various biological molecules. The combination of these two functional groups in 2-(pyrrolidin-1-ylmethyl)-1H-imidazole may offer unique properties and potential biological activities that could be of interest for further investigation and development.
Check Digit Verification of cas no
The CAS Registry Mumber 58610-69-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,8,6,1 and 0 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 58610-69:
(7*5)+(6*8)+(5*6)+(4*1)+(3*0)+(2*6)+(1*9)=138
138 % 10 = 8
So 58610-69-8 is a valid CAS Registry Number.
58610-69-8Relevant articles and documents
NRF2 REGULATORS
-
Page/Page column 123, (2017/01/02)
Provided are aryl analogs,pharmaceutical compositions containing them and their use as NRF2 regulators.
Structure and property based design of factor Xa inhibitors: Biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs
Young, Robert J.,Borthwick, Alan D.,Brown, David,Burns-Kurtis, Cynthia L.,Campbell, Matthew,Chan, Chuen,Charbaut, Marie,Convery, Maire A.,Diallo, Hawa,Hortense, Eric,Irving, Wendy R.,Kelly, Henry A.,King, N. Paul,Kleanthous, Savvas,Mason, Andrew M.,Pateman, Anthony J.,Patikis, Angela N.,Pinto, Ivan L.,Pollard, Derek R.,Senger, Stefan,Shah, Gita P.,Toomey, John R.,Watson, Nigel S.,Weston, Helen E.,Zhou, Ping
, p. 28 - 33 (2008/09/17)
Structure and property based drug design was exploited in the synthesis of sulfonamidopyrrolidin-2-one-based factor Xa (fXa) inhibitors, incorporating basic biaryl P4 groups, producing highly potent inhibitors with significant anticoagulant activities and encouraging oral pharmacokinetic profiles.